Why carry out this study?

One in four children hospitalized with COVID-19 requires intensive care.

There is an unmet need for pediatric COVID-19 treatment options during mild to moderate disease presentation for high-risk patients.

This study investigates weight-based dosing of bamlanivimab and etesevimab administered together in pediatric, ambulatory, high-risk participants with COVID-19.

What was learned from the study?

Our findings reveal similar pharmacokinetics, safety, and clinical status profiles between weight-based dosing of bamlanivimab and etesevimab in pediatrics to adults administered the authorized doses of bamlanivimab and etesevimab.

These results support the first FDA authorization of a monoclonal antibody treatment in pediatric participants aged < 12 years and reveal distinct approaches to dosing selection and to testing COVID-19 therapeutics in pediatric populations.